Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection
about
H5N1 vaccine-specific B cell responses in ferrets primed with live attenuated seasonal influenza vaccinesPhase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteersCurrent Advances in Virus-Like Particles as a Vaccination Approach against HIV InfectionVirus-like particles as antigenic nanomaterials for inducing protective immune responses in the lungSingle-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 virusesSignificant impact of sequence variations in the nucleoprotein on CD8 T cell-mediated cross-protection against influenza A virus infectionsPreclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccineFunctional testing of an inhalable nanoparticle based influenza vaccine using a human precision cut lung slice techniqueSublingual immunization with a live attenuated influenza a virus lacking the nonstructural protein 1 induces broad protective immunity in miceVirus-like particle vaccine containing hemagglutinin confers protection against 2009 H1N1 pandemic influenzaImprovement of the trivalent inactivated flu vaccine using PapMV nanoparticlesIntranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protectionVirus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in miceDNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice.Control of influenza virus infection by immunity to conserved viral features.Impact of prior seasonal H3N2 influenza vaccination or infection on protection and transmission of emerging variants of influenza A(H3N2)v virus in ferrets.Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus.Development of stable influenza vaccine powder formulations: challenges and possibilitiesAntibody contributes to heterosubtypic protection against influenza A-induced tachypnea in cotton rats.Heterosubtypic immunity to influenza A virus: where do we stand?Cross-reactive immunity to clade 2 strains of influenza virus A subtype H5N1 induced in adults and elderly patients by Fluval, a prototype pandemic influenza virus vaccine derived by reverse genetics, formulated with a phosphate adjuvant, and directDesign of a heterosubtypic epitope-based peptide vaccine fused with hemokinin-1 against influenza viruses.Prolonged protection against Intranasal challenge with influenza virus following systemic immunization or combinations of mucosal and systemic immunizations with a heat-labile toxin mutant.Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge.Influenza vaccines based on virus-like particlesDevelopment of mucosal adjuvants for intranasal vaccine for H5N1 influenza virusesAcquired heterosubtypic antibodies in human immunity for avian H5N1 influenza.Several hemagglutinins of same serotype for induction of broad immunity against influenza A virus antigenic drift variants: WO2008048984.Microneedle delivery of H5N1 influenza virus-like particles to the skin induces long-lasting B- and T-cell responses in mice.M2SR, a novel live single replication influenza virus vaccine, provides effective heterosubtypic protection in mice.Biopolymer encapsulated live influenza virus as a universal CD8+ T cell vaccine against influenza virus.Cross-protective immunity to influenza A viruses.Universal or Specific? A Modeling-Based Comparison of Broad-Spectrum Influenza Vaccines against Conventional, Strain-Matched VaccinesDevelopment of adenoviral vector-based mucosal vaccine against influenza.Yeast Surface-Displayed H5N1 Avian Influenza Vaccines.Hallmarks of CD4 T cell immunity against influenzaRegulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance.Heterosubtypic antibody response elicited with seasonal influenza vaccine correlates partial protection against highly pathogenic H5N1 virus.Targets for the induction of protective immunity against influenza a viruses.Microneedle and mucosal delivery of influenza vaccines.
P2860
Q21090076-20EC965C-6BBA-453B-8DCA-51A3BD7A8DFAQ24545856-297910BE-767D-4688-97A2-8626CF41ACD8Q26775082-9849C6A7-DAEE-477B-AFE5-6FE8C91A0929Q26825031-0186BA25-2BBD-4219-AB72-573D30FC3B79Q27318575-6009C5E1-72A0-4A7E-AAA0-B6DCB31B20F4Q27329554-A91F4BAB-0A7E-4DAA-A148-415DDDAB172CQ27347652-0DA23AB8-9430-4C67-B3DB-9E3A0B0FBAB5Q28535298-F03FD098-B835-4F78-9A02-DCD083AD8AD0Q28727930-47B521FB-CBBA-463F-9BC1-A419CB60BDA1Q28741801-C1BDF6CA-1898-4D89-BDA1-70A9EDB7DD17Q28743086-DA8E7008-053B-4525-99A7-0B0364B4DEB4Q28744570-74D9936A-9DD5-41CD-A8AA-D99C1B58986EQ28748950-70D1132D-D753-4CCE-85D6-7D2D7E51A303Q30331219-1DB3A980-D19D-48C3-A830-C08EB469D23CQ30343902-38C6791D-64C9-425D-A693-0DC722822E4CQ30354091-9DE252A9-1CBD-45B3-9431-AD5439507621Q30359424-0C35A1BC-6893-43AB-8105-B183538C07D7Q30368221-A94F5FAB-0D12-4797-9FB1-D3A603C5D751Q30368359-561BC9FA-FF3E-41CE-89E8-8BECF502C132Q30370995-81D37052-B1FC-47CC-9F76-D0BC2006AD58Q30373391-FDAF03EB-3820-40C8-B156-4E01F33BF9EDQ30373963-15BA5374-2480-4248-8A4E-D46A5F80625FQ30374752-5CB35175-5B20-4A3D-BF4C-BBA1F3F67D87Q30375784-F519965C-D27D-41DE-87C8-3304888713D6Q30376236-FE9D3606-3F9C-4838-92FF-28EB028EA7F9Q30377017-8B8E5AC2-C62E-47BE-8801-C92F722771F3Q30384441-6A773F12-5693-45D0-8471-825B1EA01580Q30385956-3ECD716F-3718-4512-98B5-2B6B079B3A84Q30391402-7C8509C5-1FA8-4160-8BCC-1659F5F300F1Q30392561-A8065442-1EC0-4E7A-A13A-CF4B87854644Q30395580-DE2F9353-C58E-4847-9155-487889985B87Q30396399-2159A360-96AA-44D1-B0FC-476081E05CAAQ30396482-961B62AB-E84A-4D69-AF7B-5EB8B907B85FQ30396642-E7DFC783-78FE-4A12-B630-DAD25F7BFFABQ30397351-E3CCB57C-68C1-4FBC-8200-AEEBDD3CE5D3Q30400290-5E35358F-104F-4C4C-9FD3-51C4A4EA62DEQ30400347-F24C9039-E45E-4318-8853-3EA9D2EBADC5Q30401524-6C320957-F949-4A50-9E10-3769EDADFC5EQ30408100-FAD9E14D-F07C-457E-82EE-D1E7603F82BBQ30418015-460105B4-2CFF-4DA0-A260-84BFE782B331
P2860
Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Mucosal delivery of inactivate ...... fluenza A H5N1 virus infection
@ast
Mucosal delivery of inactivate ...... fluenza A H5N1 virus infection
@en
type
label
Mucosal delivery of inactivate ...... fluenza A H5N1 virus infection
@ast
Mucosal delivery of inactivate ...... fluenza A H5N1 virus infection
@en
prefLabel
Mucosal delivery of inactivate ...... fluenza A H5N1 virus infection
@ast
Mucosal delivery of inactivate ...... fluenza A H5N1 virus infection
@en
P2093
P2860
P1433
P1476
Mucosal delivery of inactivate ...... fluenza A H5N1 virus infection
@en
P2093
P2860
P304
P356
10.1128/JVI.75.11.5141-5150.2001
P577
2001-06-01T00:00:00Z